TY - JOUR
T1 - Intra-abdominal desmoplastic small round cell tumor
T2 - The European pediatric Soft tissue sarcoma Study Group (EpSSG) experience
AU - Berlanga, Pablo
AU - Orbach, Daniel
AU - Schoot, Reineke A
AU - Casanova, Michela
AU - Alaggio, Rita
AU - Corradini, Nadege
AU - Brennan, Bernadette
AU - Ramirez-Villar, Gema L
AU - Hjalgrim, Lisa Lyngsie
AU - Chisholm, Julia C
AU - Bisogno, Gianni
AU - Coppadoro, Beatrice
AU - Safwat, Akmal
AU - Merks, Johannes H M
AU - Burrieza, Gabriela Guillen
AU - van Noesel, Max M
AU - Ferrari, Andrea
N1 - © 2023 Wiley Periodicals LLC.
PY - 2023
Y1 - 2023
N2 - BACKGROUND: This study describes the clinical findings of a consecutive series of pediatric and adolescent patients with a diagnosis of intra-abdominal desmoplastic small round cell tumor (DSRCT) prospectively enrolled in European pediatric Soft tissue sarcoma Study Group (EpSSG) protocols: the BERNIE study, the EpSSG MTS 2008 study, and the EpSSG NRSTS 2005 study.METHODS: Patients aged less than 21 years with a diagnosis of DSRCT arising in the abdomen were included. All trials recommended a multimodal approach including intensive multidrug chemotherapy and loco-regional treatment with surgery and/or radiotherapy whenever possible.RESULTS: The analysis included 32 cases (median age 13.7 years, male:female ratio 1.5:1). Three patients had localized tumors, seven had regionally disseminated disease, and 22 extraperitoneal metastases. All but one patient received multidrug chemotherapy and 11 had maintenance chemotherapy. Loco-regional treatment consisted of surgery only in seven cases, surgery plus adjuvant radiotherapy in 10, and radiotherapy only in six. Among the 17 cases who had radiotherapy, six had irradiation of the primary site, 10 had whole abdominopelvic radiotherapy plus boost to macroscopic residual disease, and one had irradiation to lung metastases only. With a median follow-up of 76 months (range: 18-124 months), 5-year event-free and overall survivals were 19.7% and 21.0%, respectively. Event-free survival was significantly worse for patients who did not receive loco-regional treatment (p-value .007).CONCLUSIONS: The study confirmed that the outcome of patients with DSRCT remains dismal and did not improve over recent years despite an intensive multimodal treatment approach.
AB - BACKGROUND: This study describes the clinical findings of a consecutive series of pediatric and adolescent patients with a diagnosis of intra-abdominal desmoplastic small round cell tumor (DSRCT) prospectively enrolled in European pediatric Soft tissue sarcoma Study Group (EpSSG) protocols: the BERNIE study, the EpSSG MTS 2008 study, and the EpSSG NRSTS 2005 study.METHODS: Patients aged less than 21 years with a diagnosis of DSRCT arising in the abdomen were included. All trials recommended a multimodal approach including intensive multidrug chemotherapy and loco-regional treatment with surgery and/or radiotherapy whenever possible.RESULTS: The analysis included 32 cases (median age 13.7 years, male:female ratio 1.5:1). Three patients had localized tumors, seven had regionally disseminated disease, and 22 extraperitoneal metastases. All but one patient received multidrug chemotherapy and 11 had maintenance chemotherapy. Loco-regional treatment consisted of surgery only in seven cases, surgery plus adjuvant radiotherapy in 10, and radiotherapy only in six. Among the 17 cases who had radiotherapy, six had irradiation of the primary site, 10 had whole abdominopelvic radiotherapy plus boost to macroscopic residual disease, and one had irradiation to lung metastases only. With a median follow-up of 76 months (range: 18-124 months), 5-year event-free and overall survivals were 19.7% and 21.0%, respectively. Event-free survival was significantly worse for patients who did not receive loco-regional treatment (p-value .007).CONCLUSIONS: The study confirmed that the outcome of patients with DSRCT remains dismal and did not improve over recent years despite an intensive multimodal treatment approach.
KW - EpSSG
KW - desmoplastic small round cell tumor
KW - outcome
KW - pediatric
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=85160688131&partnerID=8YFLogxK
U2 - 10.1002/pbc.30447
DO - 10.1002/pbc.30447
M3 - Journal article
C2 - 37243410
SN - 1545-5009
VL - 70
JO - Pediatric Blood & Cancer
JF - Pediatric Blood & Cancer
IS - 9
M1 - e30447
ER -